Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Jonathan Bush’s post-athenahealth startup is Zus Health, a healthcare-data infrastructure company publicly launched on June 17, 2021, with a $34 million Series A led by Andreessen Horowitz. Zus was not introduced as another conventional electronic health record. Its ambition was to give healthcare companies a shared, more usable layer for collecting, organizing, and applying patient information across disconnected systems.
Five years after launch, public company materials show continued activity: Zus announced a further $40 million financing and an Elation Health partnership in 2023, and published a March 2026 update about AI-supported clinical narratives and work with Elation and Firefly Health. Those announcements indicate product development and ongoing partnerships, but they do not independently establish revenue, profitability, valuation, or market share.
Why Jonathan Bush founded Zus Health
Bush co-founded athenahealth and led the company for roughly 22 years before leaving after its acquisition by Elliott Management and Veritas Capital. Zus represented a return to founding, but not a simple repeat of athenahealth’s model.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →athenahealth focused on software and services for healthcare organizations. Zus aimed to operate at a more foundational layer: providing data services, APIs, workflow components, and applications that other healthcare companies could use.
#1 Best Overall
In the original launch coverage, Bush described a motivation that combined business-model preference with a diagnosis of healthcare’s technology problems. He believed a platform company could be less exposed than a traditional healthcare-services business to the operational and political controversies that accompany running care operations. He also argued that healthcare startups needed infrastructure that would help them move faster despite engineering shortages, regulation, interoperability barriers, and complex administrative requirements. TechCrunch reported Bush’s rationale and the launch details.
His experience with athenahealth’s More Disruption Please program also informed the idea of building an ecosystem around healthcare innovators. The continuity is therefore strategic rather than structural: both companies sought to improve healthcare operations through technology, but Zus was designed as shared infrastructure for builders rather than as a replacement for athenahealth.
The problem Zus was trying to solve
Patient information is distributed across hospitals, primary-care practices, specialists, laboratories, pharmacies, health information exchanges, digital-health applications, PDFs, faxes, and unstructured clinical documents. Even when data can technically be exchanged, it may arrive in different formats, with duplicates, missing context, unclear dates, or limited visibility into its source.
Recommended Free Tools
Zus’s thesis was that healthcare organizations and digital-health companies need more than access to disconnected records. They need a longitudinal view that can be organized, interpreted, and placed inside the workflow where a clinician or care team is making a decision.
That distinction matters. Interoperability does not mean that every provider automatically sees every item in a patient’s history. Availability depends on network participation, technical integration, authorization, consent, source-system behavior, and the product configuration used by a customer.
Rank #2
What Zus built
At launch, Zus described itself as a shared development platform built around a shared health-data record. The idea was to let healthcare companies avoid rebuilding the same data and administrative infrastructure independently.
The company’s central product concept is now the Zus Aggregated Profile, or ZAP. Zus describes a ZAP as a consolidated patient profile assembled from multiple sources and organized into usable clinical categories. The company says it is supported by a FHIR-native data store and common-patient-record technology. Those are Zus’s descriptions of its architecture, not an independent technical audit.
Depending on the customer and use case, Zus says its capabilities can be delivered through:
- APIs: Developers can retrieve underlying data or use purpose-built “lenses” in their own applications.
- Embedded components: Zus data can be displayed within an existing clinical or operational workflow.
- Standalone applications: Customers can use browser-based or end-to-end workflow products.
- Direct EHR integrations: Data can be surfaced inside participating electronic health-record environments.
The company’s current product materials describe use cases involving medications, conditions, care teams, referrals, and other elements of clinical history. Its objective is not merely to collect more records, but to make information more usable at the point of care.
The 2021 launch and first partners
Zus was founded in 2020 and publicly launched on June 17, 2021. The launch included a $34 million Series A led by Andreessen Horowitz, with participation from F-Prime Capital, Maverick Ventures, Rock Health, Martin Ventures, and Oxeon Investments.
The early named partners were Cityblock Health, Dorsata, Firefly Health, and Oak Street Health. Planned capabilities included patient relationship management, data aggregation, medical-record standardization, shared access, and a patient portal. These announcements established the company’s initial direction, but an announced partnership should not automatically be treated as proof of large-scale commercial adoption.
What changed in 2023
On March 16, 2023, Zus announced a further $40 million financing. The round included JAZZ Venture Partners, F-Prime Capital, Maverick Ventures, and Andreessen Horowitz.
The same announcement introduced a partnership with Elation Health and placed greater emphasis on bringing external patient data into the point-of-care workflow. Through the integration, clinicians using Elation can view expanded records from hospitals, clinics, laboratories, and pharmacies within the Elation environment, subject to the relevant technical and authorization conditions.
This was strategically important because it connected Zus’s data-aggregation thesis to an established clinical workflow rather than leaving the company as a developer-facing data service. Zus’s Elation overview and technical documentation describe synchronization behavior, supported information, and patient opt-out handling.
Zus also said in a March 23, 2023 post that its Zus Grid was connected to 70 million provider sites and data on more than 270 million patients. Those are company-reported figures and should be read as such, not as independently verified measures of complete or continuously available patient coverage.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Rank #4
Where Zus stands in 2026
Zus’s public product picture has expanded beyond the original launch description. The company currently advertises data aggregation, APIs, embedded clinical components, standalone applications, and direct EHR integrations. It publicly references integrations or work involving platforms such as Elation, Canvas Medical, and Healthie, among others.
A March 31, 2026 company update describes work with Elation Health and Firefly Health to turn raw healthcare data into more usable clinical narratives and workflow insights. Zus presents this as an AI-supported effort to help clinicians interpret fragmented information. The update is a company account of that work, so it should not be read as independent evidence that the technology improves clinical outcomes.
The public record therefore supports a measured conclusion: Zus appears to remain active, has disclosed a second financing round, has developed named EHR and healthcare-company partnerships, and continues to publish product material. It does not provide enough evidence to conclude how much revenue the company generates, whether it is profitable, what its valuation is, or how many customers it retains.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.The hard questions behind the platform strategy
Can aggregation produce clinical usefulness?
More data is not automatically better care. A useful shared profile must deduplicate records, distinguish current information from historical information, show dates and provenance, and surface the facts relevant to the immediate workflow. Otherwise, the platform may create another information burden for clinicians rather than reducing one.
How reliable is patient matching?
Combining records from multiple organizations requires accurate identity matching. Incorrect matches can expose one patient’s information to another patient’s care team; missed matches can hide important history. This is one of the central operational risks for any longitudinal-record platform.
Best Value
What does “real time” mean?
Data may be retrieved in real time from a source, synchronized periodically, or made available only after a source organization has processed it. Those are materially different conditions. A buyer evaluating Zus or a comparable platform should ask which sources are connected, how often each source updates, what happens when a source is unavailable, and how the interface shows the age and origin of each item.
Does interoperability mean unrestricted sharing?
No. A shared data layer still requires governance around consent, authorization, access controls, sensitive information, correction requests, deletion requests, and applicable federal and state privacy rules. Network participation and product configuration also limit what can be displayed.
Can AI summaries be trusted?
AI-generated clinical narratives can reduce the effort required to review a large record, but they introduce a separate verification problem. Clinicians need to see the underlying evidence, understand where it came from, identify whether it is current, and correct omissions or misleading summaries. “AI-powered” should not be interpreted as autonomous diagnosis or clinical decision-making.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesWhat healthcare buyers should ask
Zus is primarily a B2B infrastructure product rather than a consumer medical-record application with public self-serve pricing. A healthcare organization or digital-health company evaluating it should ask:
- Which source networks, EHRs, laboratories, pharmacies, and document types are included?
- How are patients matched, duplicates resolved, and conflicting facts presented?
- Can users see provenance, timestamps, and the original source record?
- What consent, opt-out, authorization, and sensitive-data controls are available?
- Is the product delivered through an API, an embedded component, a standalone application, or an EHR integration?
- What implementation work is required, and who bears the integration cost?
- How are outages, stale data, missing records, and synchronization delays communicated?
- What clinical evidence supports any claimed improvement in workflow or outcomes?
- How are AI-generated narratives reviewed, corrected, and audited?
- What are the commercial terms, service-level commitments, and migration options?
No public price sheet was identified in the reviewed official material, so pricing should be treated as sales-led or contract-based unless Zus provides different terms directly.
Bottom line
Jonathan Bush’s return to entrepreneurship produced Zus Health, a data and interoperability company launched in 2021 with $34 million in funding—not a second athenahealth and not simply another EHR. Zus has since disclosed $40 million in additional financing, partnered with Elation Health, expanded its APIs and workflow products, and continued public work on AI-supported clinical narratives.
The company’s long-term test is operational: whether it can make external patient data accurate, timely, explainable, governed, and genuinely useful inside real clinical workflows. The public record shows continued development, but not enough independently verified financial or clinical evidence to declare the business a proven success.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Key sources: TechCrunch launch coverage; Zus’s 2023 financing and Elation announcement; Zus product page; Zus Grid overview; and Zus’s March 2026 update.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
